Highest-materiality recent filing
IDEAYA announces clinical collaboration with Roche for PRMT5 + pan-RAS combo in MTAP-deleted PDAC
IDE892 (PRMT5 inhibitor) to be combined with Roche's RG6505 (pan-RAS inhibitor) in MTAP-deleted, RAS-mutant pancreatic cancer.
Darovasertib + crizotinib achieved median PFS 6.9 months vs 3.1 months for investigator's choice (HR=0.42, p<0.0001) by BICR, reducing risk of progression by 58%.
IDEAYA reports positive Phase 2/3 darovasertib trial; Q1 net loss $98.5M, cash $973M
Phase 2/3 OptimUM-02 met primary endpoint: 58% risk reduction in PFS (HR 0.42, p<0.0001), median PFS 6.9 vs 3.1 months.
IDEAYA files new S-3ASR; $156.6M ATM capacity remains under Jefferies agreement
Filed new automatic shelf registration (S-3ASR) to replace expiring June 2026 shelf; effective May 5, 2026.
Darovasertib + crizotinib reduced risk of disease progression by 58% (HR 0.42, p<0.0001) in 1L HLA-A*02:01-negative mUM.
IDEAYA enters clinical collaboration with AstraZeneca for IDE849 + Imfinzi in SCLC
Collaboration to evaluate IDE849 (DLL3 TOP1 ADC) plus AstraZeneca's Imfinzi in extensive-stage SCLC.
IDEAYA expects topline PFS data from darovasertib Phase 2/3 trial by late March 2026
130 required PFS events confirmed by BICR; topline results from OptimUM-02 trial (1L HLA*A2-negative mUM) expected ~last week of March 2026.
Topline PFS results from Phase 2/3 OptimUM-02 for darovasertib+crizotinib in 1L HLA*A2-negative mUM expected Q1 2026.
GSK terminates collaboration on IDE275 and IDE705; programs returning to IDEAYA
GSK gave written notice on Dec 9, 2025 to terminate the June 2020 Collaboration, Option and License Agreement.
GSK terminates collaboration; IDEAYA regains IDE275 and IDE705; cash runway unchanged
GSK terminates Collaboration, Option and License Agreement effective 90 days after Dec 4, 2025; programs transferred back to IDEAYA.
IDEAYA reports Q3 net income $119.2M, cash $1.14B; darovasertib partnership with Servier closed
Net income of $119.2M vs Q2 net loss of $77.5M; collaboration revenue $207.8M from Servier license.
IDEAYA reports Phase 2 darovasertib data: median OS 21.1 mo in 1L mUM; 57% eye preservation
Darovasertib + crizotinib in 1L mUM: median OS 21.1 mo (historical ~12 mo), median PFS 7.0 mo, ORR 34%, DCR 90%.
IDE849 (DLL3 ADC) showed 73.2% ORR (52/71) and 47.9% confirmed ORR in SCLC at >=2.4 mg/kg; median PFS 6.7 months.
IDEAYA licenses darovasertib ex-US to Servier for $210M upfront plus milestones up to $320M
Exclusive license to Servier for darovasertib outside the US; all human diagnostic, prophylactic, therapeutic uses.
IDEAYA Q2 net loss $77.5M; cash ~$992M; darovasertib PFS data on track for YE2025
Net loss of $77.5M for Q2 2025 vs $72.2M in Q1 2025; R&D expenses $74.2M, G&A $14.6M.
IDEAYA Q1 2025 net loss $72.2M; cash ~$1.05B funds ops into 2029; darovasertib enrollment >300 pts
Cash, equivalents and securities $1.05B as of March 31, 2025, supporting updated runway into 2029.
IDEAYA reports Q4 2024 net loss of $130.3M; cash ~$1.1B, funds operations into at least 2028
Cash, equivalents and marketable securities of ~$1.1B as of Dec 31, 2024, up from $632.6M in 2023.
IDEAYA appoints Joshua Bleharski as CFO, effective May 2025
Joshua Bleharski, Ph.D., age 50, appointed Chief Financial Officer, effective early May 2025.
IDEAYA licenses DLL3 ADC SHR-4849 from Hengrui; total potential payments $1.045B
Exclusive worldwide license (ex-Greater China) for Phase 1 DLL3-targeting Topo-I-payload ADC SHR-4849.
IDEAYA reports Q3 net loss of $51.8M; cash $1.2B; progress in darovasertib and IDE397 trials
Net loss of $51.8M for Q3 2024; R&D expenses $57.2M; G&A $9.7M.
IDEAYA reports 33% ORR in Phase 1 IDE397 in MTAP-deletion urothelial cancer and NSCLC
Overall response rate 33% (1 CR, 8 PR) in 27 evaluable patients; all 9 responses confirmed.
Phase 1 expansion results for IDE397 (MAT2A inhibitor) in MTAP-deletion NSCLC and urothelial cancer to be presented as late-breaker oral on Oct 25.
59% of 49 evaluable patients had >=20% ocular tumor shrinkage; 49% had >=30% shrinkage by product of diameters.
Q2 net loss $52.8M vs $39.6M in Q1; R&D expenses $54.5M, up from $42.8M.
IDEAYA enters option/license deal with Biocytogen for B7H3/PTK7 BsADC; total potential $406.5M
Total potential payments of $406.5M including $100M development/regulatory milestones and single-digit royalties.
IDEAYA Biosciences completes $283.8M public offering of common stock and pre-funded warrants
Offered 8,355,714 common shares and pre-funded warrants for 285,715 shares at $35.00 per share/$34.9999 per warrant.
IDEAYA reports 39% ORR in IDE397 Phase 2 monotherapy for MTAP-deletion cancers
Overall response rate 39% (1 CR, 6 PRs by RECIST 1.1) in 18 evaluable MTAP-deletion urothelial cancer and NSCLC patients.
IDEAYA darovasertib Phase 2 uveal melanoma data: 75% eye saved, 47% median tumor shrinkage
Investigator-sponsored Phase 2: 75% of enucleation patients (9/12) had eye saved (converted to brachytherapy/EBRT) after 6 months.
IDEAYA Q1 net loss $39.6M, cash $941M; darovasertib UM data at ASCO, Werner IND on track
Net loss of $39.6M for Q1 2024; cash, equivalents and marketable securities $941.4M, projected to fund operations into 2028.
IDEAYA Enters Clinical Collaboration with Merck to Evaluate IDE161 + KEYTRUDA in Endometrial Cancer
Phase 1 trial will test IDE161 (PARG inhibitor) + KEYTRUDA in MSI-high and MSS endometrial cancer.
IDYA reports Q4 net loss $34M, cash $632.6M; multiple 2024 milestones
Cash $632.6M at Dec 31, 2023; Jan 2024 ATM raised ~$352M gross ($342.3M net); runway into 2028.
Dr. Kelley will resign from the Board at the end of her current term, which will conclude immediately after the Annual Meeting.
On February 10, 2025, the Board of Directors (the “Board”) of IDEAYA Biosciences, Inc. (the “Company”) appointed Joshua Bleharski, Ph.D. as Chief Financial Officer of the Company, effective early May 2025
On June 21, 2024, Jason Throne informed IDEAYA Biosciences, Inc. (the “Company”) of his voluntary resignation from his positions as Chief Legal Officer and Secretary of the Company.
Max materiality 0.85 · Median 0.70 · Most common event other_material